Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-09T15:21:37.778Z Has data issue: false hasContentIssue false

27 - Chemotherapy

from Section 5 - Gynecologic Oncology

Published online by Cambridge University Press:  01 February 2018

By
Scott D. Richard  and
Tommy R. Buchanan
Edited by
Lisa Keder  and
Martin E. Olsen
Lisa Keder
Affiliation:
Ohio State University
Martin E. Olsen
Affiliation:
East Tennessee State University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Gynecologic Care , pp. 263 - 270
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Risks of developing or dying from cancer 2016. www.cancer.orgGoogle Scholar
Pfister, D.G. Importance of economic evaluation in oncology: new economic challenges in oncology practice. World Health Cont Med Edu. 1997;2–5.Google Scholar
Skipper, H.E., Schabel, F.M., Mullett, L.B. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1950;54:431–50.Google Scholar
Johnson, S.W., Hamilton, T.C., Ozols, R.F. Mechanisms of drug resistance in ovarian cancer. Cancer. 1993;71:644–9.Google Scholar
Rosenberg, B., VanCamp, L., Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9.Google Scholar
Rosenberg, B., VanCamp, L., Trosko, J. E., Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–6.Google Scholar
Kelland, L. The resurgence of platinum-based cancer chemotherapy. www.medscape.com/viewarticle/563882. Accessed August 12, 2016.Google Scholar
Dasari, S., Tchounwou, P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014:364–78.Google Scholar
Barry, M., Behnke, C., Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990;40:2353–62.Google Scholar
Miller, R., Tadagavadi, R., Ramesh, G., Reeves, W. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;11:2490–18.Google Scholar
Natarajan, G., Malathi, R., Holler, E. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem.Pharmacol. 1999;58:1625–9.Google Scholar
Canetta, R., Rozencweig, M., Carter, S.K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985;12(Suppl A):125–36.Google Scholar
Go, S., Adjei, A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409–2.CrossRefGoogle ScholarPubMed
Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database Syst. 2000:CD001418.Google Scholar
Neijt, J.P., Engelholm, S.A., Tuxen, M.K. et al. Exploratory Phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 2000;18:3084–92.CrossRefGoogle Scholar
Ozols, R.F., Bundy, B.N., Greer, B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003;21:3194–3200.Google Scholar
Richmond, R.C. Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells. Radiat Res. 1984;99:596–60.Google Scholar
Amorino, G.P. et al. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999;44:399–405.Google Scholar
Maggi, R., Lissoni, A., Spina, F. et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer. 2006;95:266–71.CrossRefGoogle Scholar
Bryan, J. How bark from the Pacific yew tree improved the treatment of breast cancer. Phar J. (2011).Google Scholar
Abal, M., Andreu, J.M., Barasoain, I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 3:193–203.Google Scholar
McGuire, W.P., Hoskins, W.J., Brady, W.F. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996;334:1–6.Google Scholar
Rowinsky, E., Eisenhauer, E., Chaudhry, V., Arbuck, S., Donehower, R. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20(4 Suppl 3):1–15.Google ScholarPubMed
Scripture, C.D., Figg, W.D., Sparreboom, A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4(2):165–72.CrossRefGoogle ScholarPubMed
Markman, M., Kennedy, A., Webster, K. et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 2001.19:1901–5.Google Scholar
Thorn, C., Oshiro, C., Marsh, S. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011.21(7):440–6.Google Scholar
Chlebowki, R., Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med. 1979 Nov;131(5):364–8.Google Scholar
Rafiyath, S., Rasul, M., Lee, B., Wei, G., Lamba, G., Liu, D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012 Apr 23;1(1):10.Google Scholar
Homesley, H., Bundy, B., Hurteau, J., Roth, L. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999 Feb;72(2):131–7.Google ScholarPubMed
Jules-Elysee, K., White, D. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11(1):1.Google Scholar
Plunkett, W., Huang, P., Xu, Y.Z., Heinemann, V., Grunewald, R., Gandhi, V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug;22(4 Suppl 11):3–10.Google ScholarPubMed
Hansen, S. Gemcitabine in the treatment of ovarian cancer. Int J Gynecol Cancer. 2001;11(Suppl 1):39–41.Google Scholar
Treon, S., Chabner, B. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42(8 Pt 2):1322.Google Scholar
Musa, F., Blank, S., Muggia, F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):215–24.CrossRefGoogle ScholarPubMed
Coleman, R., Miller, D. Topotecan in the treatment of gynecologic cancer. Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-55–63.Google Scholar
Long, H.J., Bundy, B.N., Grendys, E.C. et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626–33.Google Scholar
Burger, R., Brady, M., Bookman, M. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473–83.CrossRefGoogle ScholarPubMed
Tewari, K., Sill, M., Long, H. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734–43.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×